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Peter Hajek1, Katie Myers Smith1, Al-Rehan Dhanji2 and Hayden McRobbie1*Abstract
Background: Nicotine replacement therapy (NRT) and varenicline are both effective in helping smokers quit. There
is growing interest in combining the two treatments to improve treatment outcomes, but no experimental data
exist on whether this is efficacious. This double-blind randomised controlled trial was designed to evaluate whether
adding nicotine patches to varenicline improves withdrawal relief and short-term abstinence rates.
Methods: 117 participants seeking help to stop smoking were randomly allocated to varenicline plus placebo
patch or varenicline plus nicotine patch (15 mg/16 hour). Varenicline use commenced one week prior to the target
quit date (TQD), patch use started on the TQD. Ratings of urges to smoke and cigarette withdrawal symptoms were
collected weekly over 4 weeks post-TQD. Medication use and smoking status were established at 1, 4 and 12
weeks. Participants lost to follow-up were included as continuing smokers.
Results: 92% of participants used both medications during the first week after the TQD. The combination
treatment generated no increase in nausea or other adverse effects. It had no overall effect on urges to smoke or
on other withdrawal symptoms. The combination treatment did not improve biochemically validated abstinence
rates at 1 week and 4 weeks post-TQD (69% vs 59%, p=0.28 and 60% vs 59%, p=0.91, in the nicotine patch and
placebo patch arm, respectively), or self reported abstinence rates at 12 weeks (36% vs. 29%, p=0.39, NS).
Conclusions: The efficacy of varenicline was not enhanced by the addition of nicotine patches, although further
trials would be useful to exclude the possibility of type II error.
Trial Registration: Clinicaltrials.gov Registration Number: NCT01184664
Keywords: Smoking cessation, Varenicline, Nicotine patchBackground
Nicotine replacement treatment (NRT) and varenicline
are both effective in helping smokers stop smoking [1,2].
Their efficacy however is limited. In routine use, the
majority of smokers receiving intensive support and
either of these two medications are likely to fail in
their attempt to quit [3]. The possibility has been
raised that combining these two medications may increase
treatment efficacy [4].* Correspondence: h.j.mcrobbie@qmul.ac.uk
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reproduction in any medium, provided the orIn terms of observable effects on smokers, the two
medications appear alike although varenicline has
antagonist as well as agonist effects. They both seem
to achieve their effect on abstinence by alleviating
the discomfort of nicotine withdrawal [1,2]. They
also make cigarettes smoked while on the medications less
rewarding and thus may facilitate extinction. The latter
effect has been demonstrated for both varenicline [5-9]
and NRT [10,11], although the evidence for the NRT
effect seems weak [11].
In terms of neuro-physiological targets, varenicline
affects primarily alpha4 beta2 nicotinic acetylcholine
receptors (nAChRs) where it has higher affinity than
nicotine and so essentially blocks nicotine effects, as well
as acting as a partial agonist [12]. Nicotine from NRTtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tobacco smoke, but delivery from NRT is much slower.
It is not clear if the central effects of the two medications
are sufficiently different to allow synergy, but if they do
differ, their combination could have several beneficial
effects. It could in theory improve withdrawal relief and/or
assist smokers who may not react much or at all to one of
them, but who may be sensitive to the effects of the other.
Another putative mechanism concerns the timing of the
treatment regimen of the two medications. Varenicline is
used for 1–2 weeks prior to quitting, concurrently
with smoking. It is possible that from the target quit
day (TQD), when nicotine intake from cigarettes
ceases, the addition of NRT to replace any effects
which nicotine from cigarettes may still have had up
to that point, could reduce post-quitting urges to
smoke and withdrawal discomfort. It is also possible
of course that the targets of the two medications
overlap too much for their combination to provide
any additional benefit, or that the receptor occupancy
provided by varenicline blocks any additional effects
of NRT.
Such hypotheses have not been experimentally evalu-
ated so far. One observational study from an in-patient
smoking cessation facility found no differences in out-
come between a cohort of patients receiving various
combinations of NRT products plus varenicline and a
cohort receiving various combinations of NRT products
alone or with bupropion [4]. The results need to be
interpreted with caution as the groups were self-selected
and the various medication combinations were not sys-
tematic. However, the study provides reassurance that
the combination of NRT and varenicline is safe and well
tolerated.
The present trial was designed to compare varenicline
alone with a combination of varenicline and nicotine patch
in effects on urges to smoke, and abstinence for up to four
weeks. This was a proof-of-concept trial, in that a positive
finding would provide a justification for a long-term
outcome trial, while a negative finding would indicate a
more definitive result as lack of efficacy during a period in
which the combination is expected to have its main effect
would be unlikely to translate into a significant effect later
on, unless type II error was present.
We included placebo patch to control for participants’
and staff expectations. We did not include study arms using
placebo varenicline. Varenicline is superior to nicotine
patches across the time period of our study [8,13,14].
Finding patches plus varenicline more effective than
patches plus placebo could just reflect the difference
between the two medications rather than any effect of
their combination. The provision of double placebo to
smokers seeking treatment also poses ethical issues.
Finding varenicline plus patches more effective thanvarenicline plus placebo on the other hand would
imply beneficial effects of the combination.
The study was authorized by the UK Medicines
and Healthcare Products Regulatory Agency (MHRA)





A double-blind randomised controlled trial was conducted
to determine if combining NRT and varenicline provides
better withdrawal and craving relief and higher abstinence
rates than varenicline alone.
Setting and participants
Smokers seeking treatment were recruited in April 2011
through local advertisments. Volunteers were included if
they were aged 18 and over, were not breastfeeding
or pregnant, and had no current psychiatric or other
serious illness.
Participants attended standard weekly support sessions
following withdrawal-oriented treatment protocol [15] as
provided by the NHS Stop-Smoking Service. The trial
took place at the Tobacco Dependence Research Unit,




Participants attended at baseline, one week prior to
TQD, on TQD, and weekly up to week 4 post-TQD.
Informed consent was taken at the baseline session.
Data were also collected over the phone at 24 hours
after the TQD. Participants were contacted for the
final follow-up 12 weeks after the TQD. Participants
received two payments of £15 at sessions one and
four weeks post-TQD.
Participants started varenicline one week before their
TQD. On the TQD they were randomised to either a
nicotine or placebo patch.
Demographic details, smoking history, and the
Fagerstrom Test for Nicotine Dependence (FTND)
[16], were collected at baseline. The Mood and Physical
Symptoms Scale (MPSS) [17], which assesses tobacco
withdrawal symptoms and urges to smoke was completed
at all contacts. MPSS asks clients to rate on a 5-point scale
how they have been feeling during the past week with
regard to depression, irritability, restlessness, hunger, poor
concentration and poor sleep at night on a scale ranging
from 1=not at all to 5=extremely. The items are analysed
separately and also aggregated to give a composite MPSS
score. To assess any effect the combination treatment may
have on the experience of nausea, we added ‘nausea’ to
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composite MPSS score. A six-point scale is used to rate
‘How much of the time have you felt the urge to smoke in
the past week?’ (from ‘not at all (1)’ to ‘all of the time (6)’)
and ‘How strong have the urges been?’ (from ‘no urges (1)’
to ‘extremely strong (6)’). The two items are aggregated to
give a composite craving score.
At each face-to-face contact, use of trial medication
since the previous contact, reports of adverse effects, self-
reported smoking status, cigarette consumption since
previous contact, and end-expired carbon monoxide
levels were assessed. The participants were weighed at
baseline and 4 weeks after TQD.
On arrival at the TQD session, participants were
sequentially allocated to the study medication by the
study staff, using a list that was computer generated
by the study statistician (M.S.). Both participants and
study staff were blind to treatment allocation. The
authors were un-blinded only after the data analysis
was completed.
Trial medications
Varenicline Commercial supplies were used as per
standard labelling (0.5 mg/d for the first 3 days, 1 mg/d
on days 4–7, followed by 2 mg/d for the rest of the
12-weeks course).
Patches Nicotine (15 mg/16 hours) and placebo patches
were identically packaged. Participants received a box
containing a four-week supply (28 patches) on their
TQD. We opted for a patch with proven efficacy [18],
which avoids sleep disturbance sometimes associated
with 24 h patch [1].
Sample size
Effective treatments typically generate a difference in
MPSS ratings over the first week of abstinence of at least
0.7 compared to control procedures [19], e.g. 1.8 (SD=1)
compared to 2.5 (SD=1). As in this case the advantage of
the combination over the first week of abstinence may
be subtle and even a difference of 0.6 would be worth
detecting, 45 participants would be needed in each group
(p<0.05, 2-tailed test, power=0.80). To allow for participant
attrition, the study aimed to randomise between 110
and 120 participants. This sample size also provides
80% power to detect a clinically meaningful difference
between abstinence rates of 50% vs 75% at four weeks
(p<0.05, 2-tailed tests).
Statistical analysis
Differences between the study arms were assessed by ana-
lysis of variance for continuous variables and chi-square for
categorical variables. The relationship between pre-quitvariables and post-quit endpoints was assessed using
regression modelling. Differences in urges to smoke at 24
hours and one week were compared using one way
ANOVA. Changes in withdrawal symptom ratings from
TQD to 24 h and one week were assessed using repeated
measures ANOVA. Differences were to be adjusted for all
baseline characteristics related to outcome that differed
between the two groups. All tests were 2-tailed.
Regarding smoking cessation outcomes, abstinence
at 24 hours and 1 week post-TQD was defined as no
smoking at all, validated by expired carbon monoxide
(CO) reading of <9 ppm. Abstinence at 4 weeks was
defined in accordance with the Russell Standard [20],
i.e. sustained abstinence since TQD validated by CO
reading at all points where CO readings were scheduled
(i.e. weeks 1–4 post-TQD), or if a session was missed, self
reported sustained abstinence and validation by a CO
reading at the next attendance. Up to 5 lapses (single
instances of smoking) since the TQD were allowed
with no smoking at all during Week 4. Participants who
did not provide a CO reading at week 4 were considered to
be smoking. Participants lost to follow-up were considered
to be smoking. Abstinence at 12 weeks was defined
as self-reported sustained abstinence since TQD (with
up to 5 lapeses allowed) but it was not biochemically
validated.
Ethical approval
Ethical approval was obtained from the NHS National
Research Ethics Service (Approval reference 10/H0709/85).
Results
A total of 117 volunteers were enrolled and randomised.
Figure 1 shows the flow of participants through the trial.
Sample characteristics
Table 1 shows the baseline charateristics of the sample.
There were no significant differences between the two
study arms.
Adherance to medications
Table 2 shows adherence to medication use at different
time points. There was no difference between the two study
arms at any time point. The adherence to medications
during the crucial first week post-TQD was high.
Eight participants did not provide data (6 in placebo
and 2 in nicotine patch arm), among the rest only
one participant was not using patches and all were
using varenicline.
Effect of varenicline and nicotine patch combination on
withdrawal symptoms
A total of 85 participants (43 in placebo patch and 42 in
nicotine patch arm) of 105 (52 in the placebo and 53 in
Potential participants 
responding to advertisements 
(n=514)
Not invited to screening (n=234)
Not meeting inclusion 
criteria (n=72)
Did not wish to participate 
(n=162)







Cannot attend sessions (n=2)
Does not want to use 
varenicline (n=1)
Randomised (n=117) Did not attend randomisation 
session (n=17)
Allocated to placebo patch 
(n=59)
Allocation Allocated to nicotine patch 
(n=58)
Completed follow up at 
12- weeks post TQD 
(n=31)
Follow-up Completed follow up at 12-
weeks post TQD (n=33)
For abstinence evaluation, 
those lost to follow-up
(n=28) were included as 
non-abstainers
Analysis For abstinence evaluation, 
those lost to follow-up
(n=25) were included as 
non-abstainers
Figure 1 Flow of participants.
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telephone at 24 hours after their TQD reported abstinence
from smoking and provided MPSS data. The two groups
did not differ in urges to smoke (2.8 vs 2.9, F=0.18, P=0.67)
or in change from baseline in the composite symptoms





Age (SD) in years 43.8 (11.0) 45.3 (10.8)
Cigarette consumption (SD) 17.4 (8.1) 18.7 (8.0)
Baseline CO (SD) 21 (10.4) 21 (8.5)
FTND (SD) 4.9 (2.6) 4.8 (2.2)
Age when started smoking (SD) 17.4 (6.8) 18.4 (5.5)
Number of previous quit attempts
(SD)
2.8 (1.1) 2.9 (1.2)
Male N (%) 40 (68) 38 (66)
White British N (%) 36 (61) 37 (64)
Married N (%) 16 (27) 15 (26)
Left school at 16 N (%) 48 (41) 46 (40)
Hand-rolled cigs N (%) 12 (20) 11 (19)
Partner smokes N (%) 15 (25) 15 (26)
In paid employment N (%) 49/58* (85) 41 (71)
Body mass Index (SD) 26 (4.6) 27 (4.8)
* Ns differ due to missing data.the TQD, 33 (placebo patch) and 40 (nicotine patch)
participants who were abstinent at that time-point
provided MPSS ratings. There was no difference between
the study arms in urges to smoke (2.7 vs 3.0, F= 2.14,
P=0.15) or in the change in the composite score (0.42 vs
0.42, F=.001, P=0.98). At four weeks after TQD, 35
(placebo patch) and 35 (nicotine patch) of participants
who achieved sustained abstinence provided MPSS data
and 34 (placebo patch) and 35 (nicotine patch) provided
urge ratings. There were no differences in urges to
smoke (2.1 vs. 2.2, F=0.08, p=0.78) or in the change
from baseline in the composite symptoms ratings
(0.05 vs. 0.01, F=0.08, p=0.78).
Looking at each withdrawal symptom at each time
point separately, there was a significant difference in the
change in depression ratings between TQD and 24 hours
post-TQD in 43 participants on placebo patch (−0.14)
and 42 participants on nicotine patch (−0.38) (F=4.10,
P=0.046). This however, was due to a higher depression
rating in the nicotine patch arm at TQD (1.21 vs 1.43 in
the placebo patch and nicotine patch arm, respectively),
i.e. prior to the initiation of the patch treatment. At 24
hours after TQD the ratings of the two groups were
similar (1.07 vs 1.05).
Among particiants abstinent for 4 weeks who provided
weight data at baseline and at 4 weeks (N=35 in the
placebo and N=35 in nicotine patch arms), the weight





Not using patch at 24 h 6/52 5/53
No use of patch in the past week at 1W post-TQD 0/53 1/56
No use of patch in the past week at 4W post-TQD 11/53 13/51
Not taken varenicline at 24 h 0/52 3/53
Not taken varenicline in the past week
at 1W post-TQD
0/53 0/57
Not taken varenicline in the past week
at 4W post-TQD
6/53 6/53
Not taken varenicline in the past week
at 3M post-TQD
23/31 24/33
* N varies dues to missing data.
Table 4 Adverse events reported by >5% of participants
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(F=4.26, p=0.04). One participant in the placebo arm lost
5.5 kg. Removing this outlier made the difference
non-significant. The two groups did not differ in their
ratings of hunger at 24 hours (0.17 vs 0.50 in the placebo
and nicotine group, respectively, F=1.45, p=0.23); 1 week
(0.53 vs 0.42, F=0.24, p=0.63) or 4 weeks post TQD (0.29
vs 0.21, F=0.1, p=0.74).
There were no differences or trends emerging for any
other single withdrawal symptom at any time-point.
Effect of varenicline and nicotine patch combination on
abstinence rates
Table 3 shows the rates of continuous validated abstinence
(not a puff since the TQD) at 24 hour and 1 week and the
Russell Standard sustained validated abstinence at 4 weeks
(up to 5 cigarettes allowed with no smoking during the
previous week). There were no differences between
the two study arms at any time point. Self-reported
sustained abstinence rates at 12 weeks were 29% vs.
36% in the placebo and nicotine patch groups, respectively
(x2 = 0.73; p = 0.39).
Varenicline non-responders
Patients who have a weak reaction to varenicline during
an extended pre-quit period have been shown to have
low success rates [5]. In theory, the addition of nicotine











24 hours N (%) 47 (80) 46 (79) x2 =.00; p = 0.96
1 week N (%) 35 (59) 40 (69) x2 =1.18; p = 0.28
4 weeks N (%) 35 (59) 35 (60) x2 =0.01; p = 0.91patients. To test this hypothesis, we evaluated separately
the effect of nicotine patches on participants who did
not reduce their CO reading by 50% or more during
their pre-TQD varenicline dosing.
There were 18 participants who reduced their CO
reading by over 50% during the pre-quit varenicline use
(varenicline reactors). Their sustained abstinence rate at
4 weeks was 78%, compared to 57% in non-reactors
(x2 = 2.85; p=0.09). Looking at the sub sample of non-
reactors only (49 in the placebo and 50 in the nicotine
patch arm), the abstinence rates at 1 and 4 weeks after
TQD were 55% and 66% (x2 = 1.23; p = 0.27) and 53%
and 60% (x2 = 0.49; p = 0.49) in the placebo patch and
nicotine patch arm, respectively. The non-reactors in the
two study arms did not differ in urges to smoke or
other withdrawal symptoms at 24 hours, 1 or 4 weeks
after TQD.
Adverse events
There were no differences in ratings of nausea between
the two groups at any time point (1.6 vs 1.5, 1.7 vs 1.8
and 1.5 vs 1.4 at 24 hour, 1 week and 4 weeks after TQD
in the placebo patch and nicotine patch arm, respectively,
all NS). There was one serious adverse event in the
placebo arm (musculoskeletal injury) that was unrelated
to the study medication.
Table 4 shows other adverse events reported by more
than 5% of participants.
Comment
Adding nicotine patches to varenicline had no beneficial
or detrimental effect on urges to smoke, withdrawal
discomfort, abstinence rates, or adverse effects profile.
Several issues need to be considered when interpreting
these results.
The study had only a short-term follow-up. This
however, would limit the generalisability of the results
primarily if the results were positive. It is unlikely
that a lack of effect during the acute withdrawal period
when stop-smoking medications exert their main impact
could change into a significant effect later on.in at least one study arm










5 12 x2 =3.5; p = 0.06
Headache 4 6 x2 =.48; p = 0.49
Insomnia 11 11 x2 =.00; p = 0.97
Nausea 26 33 x2 =1.93; p = 0.17
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in withdrawal ratings and craving and also a clinically
meaningful difference in short-term abstinence rates. We
cannot rule out a possibility of a subtle effect on abstinence
rates detectable on a large sample. Such an effect seems
unlikely though, because it would presumably be mediated
by lowering of withdrawal discomfort and craving, and
these parameters were not affected.
The negative results cannot be attributed to low
compliance with medication use, as almost all participants
used both medications during the first week after TQD
when any beneficial effects would be expected to be the
strongest. We used 16 h/15 mg patch which has extensive
evidence of its efficacy [18]. The 24 hour patch has been
shown to have stronger effects on morning urges to smoke
[21], but both types of patches have the same effect on
smoking cessation outcomes [1]. It could be argued that
other short-acting NRT formulations, which can be used
opportunistically could be more effective. This is possible,
but any gains in potentially higher efficacy of short-acting
NRT products are usually undermined by the fact that oral
NRT products and nicotine nasal spray have more side
effects and are less user-friendly then patches and generate
lower adherence. Good sustained adherence to oral
NRT products and nasal spray usually requires a
period of supervised frequent and regular use [22].
Where the expectation is that the product will be used only
occasionally, as a supplement to another treatment, the
adherence is likely to be low. Nevertheless, our results
should be generalised to alternative NRT products with
caution. There also remains a possibility of type II error, i.e.
that there is a difference but the trial did not detect it.
Adding nicotine patches to varenicline did not increase
the incidence of nausea or of any other adverse events.
There was a trend for the active patch group to report
more abnormal dreams, but the results overall raised no
concerns regarding the safety of combining the two
treatments.
One possible interpretation of the lack of synergy
between the two medications is that NRT and varenicline
achieve their effects via similar target mechanisms, which
overlap to a large or even full extent. Varenicline may act
on a more limited range of nicotinic receptors than
nicotine itself, but these seem to include those involved
crucially in the rewarding effects of smoking. By blocking
such receptors, varenicline may be limiting any potentially
beneficial effects of NRT as well. E.g. nicotine patches
normally alleviate weight gain in continuous abstainers
[23] but they had no such effect here.
Nicotine patches did not improve outcomes significantly
in the subgroup of smokers who did not have a strong
response to varenicline early on. This finding is more
tentative than the main result because there was a trend in
favour of nicotine patches and the study was not poweredfor sub sample analyses. Whether or not any patch effects
are blocked by varenicline more in varenicline responders
than in non-responders, an interesting question arises as to
whether varenicline non-responders may benefit from
NRT in the absence of varenicline. If this were the
case, treatment efficacy could be improved by switching
smokers who show no reaction to varenicline during
the pre-quit period over to NRT. Future studies
should evaluate this notion further.
The trial results have a practical implication. Finding a
positive effect would indicate that a large-scale study
with a long-term follow-up is warranted, but it would
not provide a definitive proof of efficacy. A negative result
on the other hand provides an indication that such a trial is
unlikely to yield strong positive results. There is a
widespread interest in combining NRT and varenicline
in the hope of improving treatment outcomes. The
results of this study suggest that such practice may not be
productive or economical, although further trials would
be useful to exclude the possibility of type II error.
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